198 related articles for article (PubMed ID: 22438084)
1. A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy.
Wilson S; Levy D
Bull Math Biol; 2012 Jul; 74(7):1485-500. PubMed ID: 22438084
[TBL] [Abstract][Full Text] [Related]
2. Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.
Takaku S; Terabe M; Ambrosino E; Peng J; Lonning S; McPherson JM; Berzofsky JA
Int J Cancer; 2010 Apr; 126(7):1666-74. PubMed ID: 19830696
[TBL] [Abstract][Full Text] [Related]
3. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy.
Llopiz D; Dotor J; Casares N; Bezunartea J; Díaz-Valdés N; Ruiz M; Aranda F; Berraondo P; Prieto J; Lasarte JJ; Borrás-Cuesta F; Sarobe P
Int J Cancer; 2009 Dec; 125(11):2614-23. PubMed ID: 19530254
[TBL] [Abstract][Full Text] [Related]
4. Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells.
Conroy H; Galvin KC; Higgins SC; Mills KH
Cancer Immunol Immunother; 2012 Mar; 61(3):425-31. PubMed ID: 22193988
[TBL] [Abstract][Full Text] [Related]
5. Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsuchiya H; Tsumura H
Clin Orthop Relat Res; 2012 Aug; 470(8):2288-94. PubMed ID: 22415727
[TBL] [Abstract][Full Text] [Related]
6. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.
Terabe M; Ambrosino E; Takaku S; O'Konek JJ; Venzon D; Lonning S; McPherson JM; Berzofsky JA
Clin Cancer Res; 2009 Nov; 15(21):6560-9. PubMed ID: 19861451
[TBL] [Abstract][Full Text] [Related]
7. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine.
Kao JY; Gong Y; Chen CM; Zheng QD; Chen JJ
J Immunol; 2003 Apr; 170(7):3806-11. PubMed ID: 12646647
[TBL] [Abstract][Full Text] [Related]
8. Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells.
Galvin KC; Dyck L; Marshall NA; Stefanska AM; Walsh KP; Moran B; Higgins SC; Dungan LS; Mills KH
Cancer Immunol Immunother; 2013 Jul; 62(7):1273-82. PubMed ID: 23657628
[TBL] [Abstract][Full Text] [Related]
9. An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol.
Qomlaqi M; Bahrami F; Ajami M; Hajati J
Math Biosci; 2017 Oct; 292():1-9. PubMed ID: 28713023
[TBL] [Abstract][Full Text] [Related]
10. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
11. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.
Soares KC; Rucki AA; Kim V; Foley K; Solt S; Wolfgang CL; Jaffee EM; Zheng L
Oncotarget; 2015 Dec; 6(40):43005-15. PubMed ID: 26515728
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
13. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
[TBL] [Abstract][Full Text] [Related]
14. Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta.
Jia ZC; Zou LY; Ni B; Wan Y; Zhou W; Lv YB; Geng M; Wu YZ
Cancer Immunol Immunother; 2005 May; 54(5):446-52. PubMed ID: 15750831
[TBL] [Abstract][Full Text] [Related]
15. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
[TBL] [Abstract][Full Text] [Related]
16. β-glucan restores tumor-educated dendritic cell maturation to enhance antitumor immune responses.
Ning Y; Xu D; Zhang X; Bai Y; Ding J; Feng T; Wang S; Xu N; Qian K; Wang Y; Qi C
Int J Cancer; 2016 Jun; 138(11):2713-23. PubMed ID: 26773960
[TBL] [Abstract][Full Text] [Related]
17. Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma.
Wang Q; Luan W; Warren L; Kadri H; Kim KW; Goz V; Blank S; Isabel Fiel M; Hiotis SP
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):574-582. PubMed ID: 26786094
[TBL] [Abstract][Full Text] [Related]
18. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
20. Silencing IDO2 in dendritic cells: A novel strategy to strengthen cancer immunotherapy in a murine lung cancer model.
Liu Y; Xu P; Liu H; Fang C; Guo H; Chen X; Tan M; Zhang Y; Min W
Int J Oncol; 2020 Aug; 57(2):587-597. PubMed ID: 32468023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
